Ironwood Pharma (IRWD) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
February 21, 2017 4:01 PM ESTIronwood revenue in 2016 was $274 million, an 83% increase over 2015, driven primarily by 2016 LINZESS® (linaclotide) U.S. net sales of $626 million and expansion of LINZESS commercial margin to 58%
Key pipeline milestones in linaclotide colonic release, vascular/fibrotic diseases, and uncontrolled gout programs
Multiple value-creating catalysts expected in 2017, including 2 commercial launches, 4 mid-stage clinical data readouts and 4 mid- to late-stage trial initiations
R&D Day on Thursday, March 9th to provide detailed discussion of Ironwoods strategy and execution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
